Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Kewpie Corporation has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed among 4 distinct examiners and 3 distinct art units. This indicates a relatively high degree of examiner variety for a small number of pending matters, requiring the company to navigate multiple individual perspectives simultaneously. The concentration in 3 art units suggests that while the examiners differ, the technical focus remains within a narrow range of biotechnology classifications.
Kyung Sook Chang is the busiest examiner for the company, with 1 pending office action. Because each of the examiners is handling exactly 1 pending action, the company faces unique sets of examiner preferences for every matter. Practitioners must be prepared to adapt their prosecution strategies to the specific nuances of all the examiners while respecting the standards of the art units involved. Kyung Sook Chang is one of the individuals whose specific feedback will determine the outcome of the current pending applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
| SHIAO, YIH-HORNG | 1 | 72.5% | +75.9% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| LIN, JERRY | 1 | 72.3% | +14.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18714279 | HYALURONIC ACID POWDER | SHIAO, YIH-HORNG | — |
| 17996372 | IMAGE GENERATION DEVICE, DISPLAY DEVICE, DATA CONVERSION DEVICE, IMAGE GENERATION METHOD, PRESENTATION METHOD, DATA CONVERSION METHOD, AND PROGRAM | LIN, JERRY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18874081 | Lipid Nanoparticles and Production Method for Same | CHANG, KYUNG SOOK | — |
| 18714279 | HYALURONIC ACID POWDER | SHIAO, YIH-HORNG | — |
| 18567426 | Preparation | SABILA, MERCY HELLEN | — |
| 17996372 | IMAGE GENERATION DEVICE, DISPLAY DEVICE, DATA CONVERSION DEVICE, IMAGE GENERATION METHOD, PRESENTATION METHOD, DATA CONVERSION METHOD, AND PROGRAM | LIN, JERRY | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1654 | 1 |
| 1685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18874081 | Lipid Nanoparticles and Production Method for Same | CHANG, KYUNG SOOK | 1613 | §103 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18714279 | HYALURONIC ACID POWDER | SHIAO, YIH-HORNG | — | §101§102§103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18567426 | Preparation | SABILA, MERCY HELLEN | 1654 | §102DP | Final Rejection | — | Pending | Dec 06, 2023 |
| 17996372 | IMAGE GENERATION DEVICE, DISPLAY DEVICE, DATA CONVERSION DEVICE, IMAGE GENERATION METHOD, PRESENTATION METHOD, DATA CONVERSION METHOD, AND PROGRAM | LIN, JERRY | 1685 | §101§102 | Non-Final OA | — | Pending | Oct 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial